Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 205,28 € (-7,53 %). La médiane est de 218,43 € (-1,61 %).
| Acheter |
18 |
| Conserver |
6 |
| Vendre |
1 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Glaukos outlines growth with Epioxa and iDose, but sees reimbursement risks
At the Wells Fargo conference, Glaukos presented its growth strategy centered on Epioxa (corneal health) and iDose (interventional glaucoma) and reported initial Epioxa revenues ($11m in the first full quarter, ~180 treated eyes) as well as sequential iDose growth of about $20m. Management expects a positive contribution to EPS from Q4 2024 and, given high gross margins, sees a path to operating margins of 30–40% with scale. Key uncertainties include delays in application reviews, possible changes to Medicare reimbursement (LCD) and market access; management is cautious for H2 2024 in the near term. Glaukos plans to continue advancing product launches, including a portable keratoconus screening device by the end of 2024, and expects further study data and approvals through 2027. » Plus sur de.investing.com
Glaukos hits new all-time high of $190.27 after strong Q2 results
Glaukos shares rose to a record high of $190.27; market capitalization stands at $11.03 billion. In Q2 2026 the company reported revenue of $185.6 million (+49.5% YoY), beating analysts' estimates, after which the full-year revenue guidance was raised. Following the results, several firms raised their price targets, while InvestingPro currently rates the stock as overvalued and 11 analysts revised their earnings estimates upward. The price increase follows a year-to-date gain of 111.6% and underscores positive investor sentiment toward Glaukos' growth prospects in the medtech sector. » Plus sur de.investing.com
Glaukos hits record high of $184.45 after strong Q2 results
Glaukos's stock rose to a record high of $184.45, bringing market capitalization to $10.83 billion. In the second quarter of 2026 the medical device company generated $185.6 million in revenue (+50% year‑on‑year) and reported a loss per share that was smaller than expected, after which Glaukos raised its full‑year revenue guidance. Several analysts lifted their price targets, while an InvestingPro analysis classifies the stock at current levels as possibly overvalued. » Plus sur de.investing.com
Glaukos raises full-year forecast after strong Q2 with 49.54% revenue growth
Glaukos reported a 49.54% revenue increase to $185.61 million in the second quarter, significantly beating analysts’ expectations. Management has sharply raised the full-year forecast, prompting heavy accumulation of the stock on high trading volume. The commercial breakthrough of the glaucoma implant iDose TR is viewed as a driver of long-term dynamic growth. » Plus sur finanzen.net
Glaukos reaches 52-week high at $161.67
Glaukos shares climbed to a new 52-week high of $161.67; the stock is currently trading at $163.01, about 1% above that high. Over the past year the stock rose 70.14%, year-to-date it is up 34%, and it gained 27% in the last six months. InvestingPro currently rates the stock as significantly overvalued. Glaukos also reported completion of patient recruitment for the phase-2 study of GLK-321; analysts including Stifel, Piper Sandler and William Blair reiterate positive views and see potential for products such as iDose and Epioxa. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 186,31 M | 63,73 % |
| Bénéfice brut | 158,79 M | 77,97 % |
| Bénéfice net | 1,78 M | 112,88 % |
| EBITDA | 10,91 M | 376,36 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 13,11 Md € |
Nombre d'actions | 59,2 M |
Plus haut/bas sur 52 semaines | 232,26 € - 79,47 € |
| Dividendes | Non |
Bêta | 0,69 |
Ratio P/E | -82,74 |
Ratio PEG | 0,73 |
Ratio P/B | 20,04 |
Ratio P/S | 20,86 |
Profil de l'entreprise
Glaukos Corporation, une entreprise de technologie médicale ophtalmique et de produits pharmaceutiques, se concentre sur le développement de nouvelles thérapies pour le traitement du glaucome, des troubles cornéens et des maladies rétiniennes. Elle propose iStent, iStent inject et iStent inject W, des stents de micro-dérivation qui améliorent l'écoulement de l'humeur aqueuse et sont implantés lors d'une chirurgie de la cataracte pour traiter le glaucome à angle ouvert léger à modéré. Le pipeline produit de l'entreprise comprend iStent Infinite, un produit à trois stents conçu pour être utilisé comme procédure autonome chez les patients atteints de glaucome réfractaire, ainsi que iDose TR, un implant injectable ciblé basé sur sa plateforme de dispositifs à micro-échelle, conçu pour délivrer des niveaux thérapeutiques de médicament. L'entreprise commercialise ses produits par l'intermédiaire d'une organisation de vente directe, ainsi que par le biais de distributeurs aux États-Unis et à l'international. Glaukos Corporation a été constituée en 1998 et son siège social se situe à San Clemente, en Californie.
| Nom | Glaukos |
| PDG | Thomas William Burns |
| Siège social | Aliso Viejo,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Biens de consommation durables |
| Introduction en bourse | 03/12/2009 |
| Employés | 1 094 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | GKOS |
Frankfurt | 6GJ.F |
Düsseldorf | 6GJ.DU |
München | 6GJ.MU |